Aminoglycosides and renal magnesium homeostasis in humans

Détails

ID Serval
serval:BIB_8A51ADAE620F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Aminoglycosides and renal magnesium homeostasis in humans
Périodique
Nephrology, Dialysis, Transplantation
Auteur(s)
von Vigier  R. O., Truttmann  A. C., Zindler-Schmocker  K., Bettinelli  A., Aebischer  C. C., Wermuth  B., Bianchetti  M. G.
ISSN
0931-0509 (Print)
Statut éditorial
Publié
Date de publication
06/2000
Volume
15
Numéro
6
Pages
822-6
Notes
Journal Article --- Old month value: Jun
Résumé
BACKGROUND: The use of aminoglycosides has been linked with hypomagnesaemia in scattered reports. The objective of the study was to measure prospectively the effect of treatment with the aminoglycoside amikacin on renal magnesium homeostasis. METHODS: Twenty-four cystic fibrosis patients (aged 9-19 years) admitted because of exacerbation of pulmonary symptoms caused by Pseudomonas aeruginosa were treated with the aminoglycoside amikacin and the cephalosporin ceftazidime for 14 days. Renal values and plasma and urinary electrolytes were measured before and at the end of the systemic anti-pseudomonal therapy. RESULTS: In the patients with cystic fibrosis, treatment with amikacin and ceftazidime did not modify plasma creatinine or urea and plasma or urinary sodium, potassium and calcium. Treatment with amikacin and ceftazidime significantly decreased both plasma total magnesium (from 0.77 (0. 74-0.81) to 0.73 (0.71-75) mmol/l; median and interquartile range) and ionized magnesium (from 0.53 (0.50-0.55) to 0.50 (0.47-0.52) mmol/l) concentration and increased fractional urinary magnesium excretion (from 0.0568 (0.0494-0.0716) to 0.0721 (0.0630-0.111)) and total urinary magnesium excretion (from 30.7 (26.5-38.0) to 38.5 (31. 5-49.0) micromol/l glomerular filtration rate). CONCLUSIONS: The present study demonstrates that systemic therapy with amikacin plus ceftazidime causes mild hypomagnesaemia secondary to renal magnesium wasting even in the absence of a significant rise in circulating creatinine and urea.
Mots-clé
Adolescent Amikacin/therapeutic use Anti-Bacterial Agents/*therapeutic use Ceftazidime/therapeutic use Cephalosporins/therapeutic use Child Cystic Fibrosis/complications/*metabolism Drug Therapy, Combination/*therapeutic use Electrolytes/blood/urine Female Homeostasis Humans Kidney/drug effects/*metabolism Lung Diseases/complications/*drug therapy/microbiology Magnesium/*metabolism Male Pseudomonas Infections/complications/*drug therapy Pseudomonas aeruginosa
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/01/2008 14:50
Dernière modification de la notice
08/05/2019 21:39
Données d'usage